Eversept Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $10.8M | Sell |
1,207,638
-964,798
| -44% | -$8.64M | 1% | 28 |
|
|
2025
Q1 | $16.3M | Buy |
2,172,436
+192,124
| +10% | +$1.44M | 1.65% | 20 |
|
|
2024
Q4 | $14.9M | Buy |
1,980,312
+1,444,907
| +270% | +$10.9M | 1.32% | 16 |
|
|
2024
Q3 | $4.07M | Sell |
535,405
-617,168
| -54% | -$4.69M | 0.28% | 41 |
|
|
2024
Q2 | $7.12M | Sell |
1,152,573
-279,854
| -20% | -$1.73M | 0.49% | 35 |
|
|
2024
Q1 | $7.28M | Sell |
1,432,427
-96,620
| -6% | -$491K | 0.49% | 38 |
|
|
2023
Q4 | $9.16M | Sell |
1,529,047
-950,056
| -38% | -$5.69M | 0.8% | 26 |
|
|
2023
Q3 | $17.6M | Buy |
2,479,103
+106,990
| +5% | +$757K | 1.49% | 15 |
|
|
2023
Q2 | $16.7M | Sell |
2,372,113
-2,148,611
| -48% | -$15.1M | 1.4% | 16 |
|
|
2023
Q1 | $37.7M | Buy |
4,520,724
+3,640,237
| +413% | +$30.4M | 2.63% | 10 |
|
|
2022
Q4 | $10.1M | Buy |
+880,487
| New | +$10.1M | 0.89% | 24 |
|
|
2021
Q1 | – | Sell |
-491,852
| Closed | -$3.66M | – | 80 |
|
|
2020
Q4 | $3.66M | Sell |
491,852
-651,359
| -57% | -$4.85M | 0.43% | 35 |
|
|
2020
Q3 | $3.93M | Sell |
1,143,211
-3,704,581
| -76% | -$12.7M | 0.87% | 27 |
|
|
2020
Q2 | $23.1M | Sell |
4,847,792
-2,694,580
| -36% | -$12.8M | 3.17% | 11 |
|
|
2020
Q1 | $15.1M | Buy |
7,542,372
+2,637,912
| +54% | +$5.28M | 3.75% | 10 |
|
|
2019
Q4 | $16.9M | Buy |
4,904,460
+4,250,000
| +649% | +$14.7M | 2.99% | 10 |
|
|
2019
Q3 | $1.88M | Buy |
654,460
+312,000
| +91% | +$894K | 0.58% | 37 |
|
|
2019
Q2 | $1.3M | Sell |
342,460
-70,416
| -17% | -$267K | 0.36% | 43 |
|
|
2019
Q1 | $3.36M | Buy |
412,876
+248,917
| +152% | +$2.03M | 0.98% | 23 |
|
|
2018
Q4 | $1.32M | Buy |
163,959
+15,000
| +10% | +$121K | 0.72% | 28 |
|
|
2018
Q3 | $1.14M | Hold |
148,959
| – | – | 0.5% | 32 |
|
|
2018
Q2 | $854K | Hold |
148,959
| – | – | 0.39% | 43 |
|
|
2018
Q1 | $711K | Sell |
148,959
-49,360
| -25% | -$235K | 0.33% | 43 |
|
|
2017
Q4 | $974K | Buy |
+198,319
| New | +$974K | 0.56% | 30 |
|